Epidemiology, pathogenesis and treatment of irritable bowel syndrome

Bibliography

• DROSSMAN DA, CORAZZIARI E, TALLEY NJ, THOMPSON WG, WHITEHEAD WE: Rome II: a multinational consensus document on functional gastrointestinal disorders. Gut (1999) 45 (Suppl.II) :1–81.
   Google Scholar
• DROSSMAN DA, CAMILLERI M, MAYER E, WHITEHEAD WE: AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 123:2108–2131.
   PubMed Web of Science ®Google Scholar
• OLDEN KW: Diagnosis of irritable bowel syndrome. Gastroenterology (2002) 122:1701–1714.
   PubMed Web of Science ®Google Scholar
• ••An excellent review on the diagnosis of IBS.
   Google Scholar
• MANNING AP, THOMPSON WG, HEATON KW, MORRIS AF: Towards positive diagnosis of irritable bowel. BE Med. J. (1978) 2:653–654.
   PubMed Web of Science ®Google Scholar
• THOMPSON WG: Gender differences in irritable bowel symptoms. Eur. Gastroenterol. Hepatol. (1997) 9:299–302.
   PubMed Web of Science ®Google Scholar
• SMITH RC, GREENBAUM DS, VANCOUVER JB et al.: Gender differences in Manning criteria in the irritable bowel syndrome. Gastroenterology (1991) 100:591–595.
   PubMedGoogle Scholar
• VANNER SJ, DEPEW WT, PATERSON WG et Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am. J. Gastroenterol. (1999) 94:2912–2917.
   PubMed Web of Science ®Google Scholar
• SCIARRETTA G, FURNO A, MORRONG B, MALAGUTI P: Absence of histopathological changes of ileum and colon in functional chronic diarrhea associated with bile acid malabsorption, assessed by SeHCAT test: a prospective study. Am. J. Gastroenterol. (1994) 89:1058–1061.
   PubMedGoogle Scholar
• KOIDE A, YAMAGUCHI T, ODAKA T et al.: Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome. Am. I Gastroenterol. (2000) 95:1735–1741.
   PubMed Web of Science ®Google Scholar
• AWAD RA, MARTIN J, CAL Y et al.: Transrectal ultrasonography: relationship with anorectal manometry, electromyography and sensitivity tests in irritable bowel syndrome. Int. J. Colored. Dis. (1998) 13:82–87.
   PubMedGoogle Scholar
• AWAD RA, MARTIN J, GUEVARA M et al.: Defaecography in patients with irritable bowel syndrome and healthy volunteers. Int. J. Colorect. Dis. (1997) 12:91–94.
   PubMedGoogle Scholar
• SCHMIDT T, HACKELSBERGER N, WIDMER R, MEISEL C, PFEIFFER A, KAESS H: Ambulatory 24-hour jejunal motility in diarrhea-predominant irritable bowel syndrome. Scand. Gastroenterol (1996) 31:581–589.
   PubMed Web of Science ®Google Scholar
• DROSSMAN DA, LI A, ANDRUZZI E et al.: US householder survey of functional gastrointestinal disorders: prevalence, sociodemography and health impact. Dig. Dis. Sci. (1993) 38:1569–1630.
   PubMed Web of Science ®Google Scholar
• SANDLER R: Epidemiology of irritable bowel syndrome in the United States. Gastroenterology (1990) 99:409–415.
   PubMed Web of Science ®Google Scholar
• HEATON KW, O'DONNELL LJD, BRADDON FEM et al.: Symptoms of irritable bowel syndrome in a British urban community: consulters and non-consulters. Gastroenterology (1992) 102:1962–1967.
   Google Scholar
• JONES R, LYDEARD S: Irritable bowel syndrome in the general population. BE Med. J. (1992) 304:87–90.
   PubMed Web of Science ®Google Scholar
• AGREUS L, SVARDSUDD K, NYREN O et al.: Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology (1995) 109:671–680.
   PubMed Web of Science ®Google Scholar
• TALLEY NJ, BOYCE PM, JONES M: Predictors of health care seeking for irritable bowel syndrome: a population based study. Gut (1997) 41:394–398.
   PubMed Web of Science ®Google Scholar
• EVERHART JE, RENAULT PF: Irritablebowel syndrome in office-based practice in the United States. Gastroenterology (1991) 100:998–1005.
   PubMed Web of Science ®Google Scholar
• MITCHELL CM, DROSSMAN DA: Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology (1987) 92:1282–1284.
   PubMed Web of Science ®Google Scholar
• RUSSO MW, GAYNES BN, DROSSMAN DA: A national survey of practice patterns of gastroenterologists with comparison to the past two decades. Clin.Gastroenterol (1999) 29:339–343.
   Google Scholar
• AMERICAN GASTROENTEROLOGICAL ASSOCIATION STATEMENT: Irritable bowel syndrome. Gastroenterology (2002) 123:2105–2107.
   PubMedGoogle Scholar
• ••An excellent review of IBS.
   Google Scholar
• TALLEY NJ, O'KEEFE EA, ZINSMEISTER AR et al.: Prevalence of gastrointestinal symptoms in the elderly: a population-based study. Gastroenterology(1992) 102:895–901.
   Google Scholar
• TALLEY NJ, ZINSMEISTER AR, VAN DYKE C et al: Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology (1991) 101:927–934.
   PubMed Web of Science ®Google Scholar
• TALLEY NJ, ZINSMEISTER AR, MELTON LJ: Irritable bowel syndrome in a community: symptom subgroups, risk factors and health care utilization. Am. J. Epidemiol (1995) 142:76–83.
   PubMed Web of Science ®Google Scholar
• TAUB E, CUEVAS JL, COOK EW et al: Irritable bowel syndrome defined by factor analysis. Gender and race comparisons. Dis. Sci. (1995) 40:1647–1655.
   Google Scholar
• TALLEY NJ, HOLTMANN G, AGREUS L et al.: Gastrointestinal symptoms and subjects cluster into distinct upper and lower groupings in the community: a four nations study. Am. J. Gastroenterof (2000) 95:1439–1447.
   PubMed Web of Science ®Google Scholar
• THOMPSON WG, LONGSTRETH GF, DROSSMAN DA, HEATON KW, IRVINE EJ, MUELLER-LISSNER SA: Functional bowel disorders and functional abdominal pain. In: Rome II: functional gastrointestinal disorders: diagnosis, pathophysiology, and treatment (2nd edn). Drossman DA, Talley NJ, Thompson WG, Whitehead WE, Corazziari E (Eds), Degnon Associates, Inc., McLean, VA, USA (2000):351–432.
   Google Scholar
• CHANG L, HEITKEMPER MM: Genderdifferences in IBS. Gastroenterology (2002) 123:1686–1701.
   PubMed Web of Science ®Google Scholar
• LOCKE GR, YAWN BP, WOLLAN PC, LYDICK E: The incidence of clinically diagnosed irritable bowel syndrome in the community (abstr). Gastroenterology (1999) 116:A76.
   Web of Science ®Google Scholar
• LEE OY, MAYER EA, SCHMULSON M, CHANG L, NALIBOFF B: Gender-related differences in IBS symptoms. Am. J. Gastroenterol (2001) 96:2184–2193.
   PubMedGoogle Scholar
• TALLEY NJ: Diagnosing an irritable bowel:does sex matter? Gastroenterology (1991) 100:834–837.
   PubMedGoogle Scholar
• TALLEY NJ, BOYCE P, JONES M: Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut (1998) 42:690–695.
   PubMed Web of Science ®Google Scholar
• SIMREN M, ABRAHAMSSON H, SVEDLUND J, BJORNSSON ES: Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern. Scand. JGastroenterol (2001) 36:545–552.
   PubMed Web of Science ®Google Scholar
• SMITH RC, GREENBAUM DS, VANCOUVER JB et al.: Gender differences in Manning criteria in the irritable bowel syndrome. Gastroenterology(1991) 100:591–595.
   PubMedGoogle Scholar
• THOMPSON WG: Gender differences in irritable bowel syndromes. Eur. JGastroenterol Hepatol (1997) 9:299–302.
   PubMed Web of Science ®Google Scholar
• ••A great review of gender differences in IBS.
   Google Scholar
• CAMILLERI M, MAYER E, DROSSMAN DA et al.: Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment. Pharmacol Ther. (1999) 13:1149–1159.
   PubMed Web of Science ®Google Scholar
• MULLER-LISSNER SA, FUMAGALLI I, BARDHAN KD et al.: Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment. Pharmacol Ther. (2001) 15:1655–1666.
   PubMed Web of Science ®Google Scholar
• KOCH KM, PALMER JL, NOORDIN N, TOMLINSON JJ, BAIDOO C: Sex and age differences in the pharmacokinetics of alosetron. Br. j Clin. Pharmacol (2002) 53:238–242.
   PubMed Web of Science ®Google Scholar
• NISHIZAWA S, BENKELFAT C, YOUNG SN et al.: Differences between males and females in rates of serotonin synthesis in human brain. Proc. Nati Acad. Sci. USA (1997) 94:5308–5313.
   PubMed Web of Science ®Google Scholar
• LEVY RL, VON KORFF M, WHITEHEAD WE et al.: Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am. J. Gastoenterol (2001) 96:3122–3129.
   PubMed Web of Science ®Google Scholar
• SANDLER RS, EVERHART JE, DONWITZ M et al.: The burden of selected digestive diseases in the United States. Gastroenterology (2002) 122:1500–1511.
   PubMed Web of Science ®Google Scholar
• WHITEHEAD WE, PALSSON O, JONES KR: Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology (2002) 122:1140–1156.
   PubMed Web of Science ®Google Scholar
• WHITEHEAD WE, CHESKIN LJ, HELLER BR et al: Evidence for exacerbation of irritable bowel syndrome during menses. Gastroenterology (1990) 98:1485–1489.
   PubMed Web of Science ®Google Scholar
• BURNS DG: The risk of abdominal surgery in irritable bowel syndrome (abstr). South Afr. Med. J. (1986) 70:91.
   PubMedGoogle Scholar
• GRALNEK IM, HAYS RD, KILBOURNE A et al: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology (2000) 119:654–660.
   PubMed Web of Science ®Google Scholar
• WELLS NEJ, HAHN BA, WHORWELL PJ: Clinical economics review: irritable bowel syndrome. Aliment. Pharmacol Ther. (1997) 11:1019–1030.
   PubMedGoogle Scholar
• WHITEHEAD WE, BURNETT CK, COOK EW, TAUB E: Impact of irritable bowel syndrome on quality of life. Dis. Sci. (1996) 41:2248–2253.
   PubMed Web of Science ®Google Scholar
• CHASSANY O, MARQUIS P, FRAITAG B et al.: European psychometric validation of a specific quality of life questionnaire in functional digestive disorders. Therapie (1995) 50\(Supp1.1):A35.
   Google Scholar
• STRASSELS SA, HAHN BA: Short form 36 (SF-36) scores in patients with IBS compared with US norms (abstr). Gastroenterology (1997) 112(Suppl.):A44.
   Google Scholar
• SERRA J, AZPIROZ F, MALAGELADA JR: Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut (2001) 48:14–19.
   PubMed Web of Science ®Google Scholar
• KELLOW JE, LANGELUDDECKE PM, ECKERSLEY GM, JONES MP, TENNANT CC: Effects of acute psychologic stress on small-intestinal motility in health and the irritable bowel syndrome. Scand. Gastroenterol (1992) 27:53–58.
   PubMed Web of Science ®Google Scholar
• WHITEHEAD WE, DRESCHER VM: Perception of gastric contractions and self-control of gastric motility. Psychophysiology (1980) 17:552–558.
   PubMed Web of Science ®Google Scholar
• ROGERS J, HENRY MM, MISIEWICZ JJ: Increased segmental activity and intraluminal pressures in the sigmoid colon of patients with the irritable bowel syndrome. Gut (1989) 30:634–641.
   PubMed Web of Science ®Google Scholar
• WELGAN E MESHKINPOUR H, BEELER M: Effect of anger on colon motor and myoelectric activity in irritable bowel syndrome. Gastroenterology(1988) 94:1150–1156.
   PubMedGoogle Scholar
• FUKUDO S, SUZUKI J: Colonic motility, autonomic function, and gastrointestinal hormones under psychological stress on IBS. Tohoku J. Exp. Med. (1987) 151:373–385.
   PubMedGoogle Scholar
• FUKUDO S, NOMURA T, HONGO M: Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut (1998) 42:845–849.
   PubMed Web of Science ®Google Scholar
• KELLOW JE, PHILLIPS SF: Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology (1987) 92:1885–1893.
   PubMed Web of Science ®Google Scholar
• RITCHIE J: Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut (1973) 14(2):125–132.
   PubMed Web of Science ®Google Scholar
• WHITEHEAD WE, HOLTKOTTER B, ENCK P et al.: Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology (1990) 98:1187–1192.
   PubMed Web of Science ®Google Scholar
• LEMBO T, MUNAKATA J, MERTZ H Evidence for the hypersensitivity of lumbar splanchnic afferents in irritable bowel syndrome. Gastroenterology(1994) 107:1686–1696.
   PubMed Web of Science ®Google Scholar
• BRADETTE M, DELVAUX M, STAUMONT G, FIORAMONTI J, BUENO L, FREXINOS J: Evaluation of colonic sensory thresholds in IBS patients using a barostat. Definition of optimal conditions and comparison with healthy subjects. Dig. Dis. Sci (1994) 39:449–457.
   Google Scholar
• MERTZ H, NALIBOFF B, MUNAKATA J, NIAZI N, MAYER EA: Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology (1995) 109:40–52.
   PubMed Web of Science ®Google Scholar
• WHITEHEAD WE, PALSSON OS: Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. Gastroenterology (1998) 115:1263–1271.
   PubMed Web of Science ®Google Scholar
• KELLOW JE, ECKERSLEY CM, JONES MP: Enhanced perception of physiological intestinal motility in the irritable bowel syndrome. Gastroenterology (1991) 101:1621–1627.
   PubMed Web of Science ®Google Scholar
• SERRA J, AZPIROZ F, MALAGELADA JR: Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut (2001) 48:14–19.
   PubMed Web of Science ®Google Scholar
• ACCARINO AM, AZPIROZ F, MALAGELADA JR: Symptomatic responses to stimulation of sensory pathways in the jejunum. Am. J. Physiol (1992) 263:G673–G677.
   Google Scholar
• TRIMBLE KC, FAROUK R, PRYDE A, DOUGLAS S, HEADING RC: Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig. Dis. Sci. (1995) 40:1607–1613.
   PubMed Web of Science ®Google Scholar
• FRANCIS CY, HOUGHTON LA, WHORWELL PJ, MORRIS J, BRADBURY J: Enhanced sensitivity of the whole gut in patients with irritable bowel syndrome (IBS). Gastroenterology (1995) 108:A60.
   Google Scholar
• ZIGHELBOIM J, TALLEY NJ, PHILLIPS SF, HARMSEN WS, ZINSMEISTER AR Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin Type 3 antagonism. Dig. Dis. Sci. (1995) 40:819–827.
   Google Scholar
• ACCARINO AM, AZPIROZ F, MALAGELADA JR: Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome. Gastroenterology (1995) 108:636–643.
   PubMed Web of Science ®Google Scholar
• EVANS PR, BENNETT EJ, BAK YT, TENNANT CC, KELLOW JE: Jejunal sensorimotor dysfunction in irritable bowel syndrome: clinical and psychosocial features. Gastroenterology (1996) 110:393–404.
   PubMed Web of Science ®Google Scholar
• HOLTMANN G, GOEBELL H, TALLEY NJ: Functional dyspepsia and irritable bowel syndrome: is there a common pathophysiological basis?. Am. J. Gastroenterol (1997) 92:954–959.
   PubMed Web of Science ®Google Scholar
• KELLOW JE, PHILLIPS SF, MILLER LJ, ZINSMEISTER AR: Dysmotility of the small intestine in irritable bowel syndrome. Gut (1988) 29:1236–1243.
   PubMed Web of Science ®Google Scholar
• ROSSEL P, DREWES AM, PETERSEN P, NIELSEN J, ARENDT-NIELSEN L: Pain produced by electric stimulation of the rectum in patients with irritable bowel syndrome: further evidence of visceral hyperalgesia. Scand. Gastroenterol (1999) 34:1001–1006.
   PubMed Web of Science ®Google Scholar
• ACCARINO AM, AZPIROZ F, MALAGELADA JR: Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome. Gastroenterology (1995) 108:636–643.
   PubMed Web of Science ®Google Scholar
• CHANG L, MAYER EA, JOHNSON T, FITZGERALD LZ, NALIBOFF B: Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia. Pain (2000) 84:297–307.
   PubMed Web of Science ®Google Scholar
• COOK IJ, VAN EEDEN A, COLLINS SM: Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology (1987) 93:727–733.
   PubMed Web of Science ®Google Scholar
• GUI XY: Mast cells: a possible link between psychological stress, enteric infection, food allergy and gut hypersensitivity in the irritable bowel syndrome. J. Gastroenterol Hepatol (1998) 13:980–989.
   PubMed Web of Science ®Google Scholar
• MAYER EA: The neurobiology of stress and gastrointestinal disease. Gut (2000) 47:861–869.
   PubMed Web of Science ®Google Scholar
• SILVERMAN DHS, MUNAKATA JA, ENNES H, MANDELKERN MA, HOH CK, MAYER EA: Regional cerebral activity in normal and pathologic perception of visceral pain. Gastroenterology(1997) 112:64–72.
   PubMedGoogle Scholar
• NALIBOFF BD, DERBYSHIRE SWG, MUNAKATA J et al: Cerebral activation in irritable bowel syndrome patients and control subjects during rectosigmoid stimulation. Psychosom. Med. (2001) 63:365–375.
   PubMedGoogle Scholar
• BACIU MV, BONAZ BL, PAPILLON E et al: Central processing of rectal pain: a functional MRI study. AMR Am. Neuroradiol. (1999) 20:1920–1924.
   PubMedGoogle Scholar
• HOBDAY DI, AZIZ Q, THACKER N, HOLLANDER I, JACKSON A, THOMPSON DG: A study of the cortical processing of ano-rectal sensation using functional MRI. Brain (2001) 124:361–368.
   PubMedGoogle Scholar
• VOGT BA, NIMCHINSKY EA, VOGT LJ, HOF PR: Human cingulate cortex: surface features, flat maps, and cytoarchitecture. J. Comp. Neurol. (1995) 359:490–506.
   PubMed Web of Science ®Google Scholar
• BUSH G, LUU P, POSNER MI: Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn. Sci. (2000) 4:215–222.
   PubMed Web of Science ®Google Scholar
• DROSSMAN DA, SANDLER RS, MCKEE DC, LOVITZ AJ: Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology (1982) 83:529–534.
   Google Scholar
• DROSSMAN DA: The role of psychosocialfactors in gastrointestinal illness. Scand. Gastroenterol (1996) 221 (Suppl.):1–4.
   Google Scholar
• DROSSMAN DA, LESERMAN J, NACHMAN G et al.: Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann. Inter Med. (1990) 113:828–833.
   PubMed Web of Science ®Google Scholar
• DROSSMAN DA, LI Z, LESERMAN J, TOOMEY TC, HU YJ: Health status by gastrointestinal diagnosis and abuse history. Gastroenterology (1996) 110:999–1007.
   PubMed Web of Science ®Google Scholar
• LYDIARD RB: Irritable bowel syndrome, anxiety, and depression: what are the links? J. Chit. Psych. (2001) 62(Suppl.):38–45.
   Google Scholar
• YOUNG SJ, ALPERS DH, NORLAND CC, WOODRUFF RA Jr: Psychiatric illness and the irritable bowel syndrome. Practical implications for the primary physician. Gastroenterology (1976) 70:162–166.
   Google Scholar
• BLANCHARD EB, KEEFER L, PAYNE A, TURNER SM, GALOVSKI TE: Early abuse, psychiatric diagnoses and irritable bowel syndrome. Behav. Res. Ther. (2002) 40(3)289–298.
   Google Scholar
• MASAND PS, KAPLAN DS, GUPTA S et al: Major depression and irritable bowel syndrome: is there a relationship? J. Clin. Psych. (1995) 56(8):363–367.
   Google Scholar
• NEAL KR, HEBDEN J, SPILLER R: Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BE Med. J. (1997) 314:779–782.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ LA, RUIGOMEZ A: Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BE Med. J. (1999) 318:565–566.
   PubMed Web of Science ®Google Scholar
• MCKENDRICK MW, READ NW: Irritable bowel syndrome post salmonella infection. J. Infect. (1994) 29:1–3.
   PubMed Web of Science ®Google Scholar
• BARBER R, BLAKEY A: Prevalence of gastrointestinal symptoms after bacterial gastroenteritis: study did not include control group. Br. Med. J. (1997) 314:1903.
   PubMedGoogle Scholar
• GWEE KA, LEONG YL, GRAHAM C et al.: The role of psychological and biological factors in postinfective gut dysfunction. Gut (1999) 44:400–406.
   PubMed Web of Science ®Google Scholar
• SPILLER RC, JENKINS D, THORNLEY JP et al: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut (2000) 47:804–811.
   PubMed Web of Science ®Google Scholar
• TORNBLOM H, LINDBERG G, NYBERG B, VERESS B: Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology (2002) 123:1972–1979.
   PubMed Web of Science ®Google Scholar
• CHADWICK VS, CHEN W, SHU D et al: Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology (2002) 122:1778–1783.
   PubMed Web of Science ®Google Scholar
• WESTON AP, BIDDLE WL, BHATIA PS, MINER PB Jr: Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig. Dis. Sci. (1993) 38:1590–1595.
   PubMed Web of Science ®Google Scholar
• O'SULLIVAN M, CLAYTON N, BRESLIN NP et al: Increased mast cells in the irritable bowel syndrome. Neurogastroenterology Motility (2000) 12:449–457.
   PubMed Web of Science ®Google Scholar
• DUNLOP S, JENKINS D, SPILLER R: Distinctive histological patterns of chronic inflammatory cells in rectal biopsies of patients with different clinical subtypes of IBS (Abstr). Gastroenterology (2002) 122:A–316.
   Google Scholar
• CAMILLERI M: Serotonergic modulation of visceral sensation: lower gut. Gut (2002) 51S:i81–i86.
   Google Scholar
• BALSARI A, CECCARELLI A, DUBINI F, FESCE E, POL G: The faecal microbial population in the irritable bowel syndrome. Microbiologica (1982) 5:185–194.
   PubMed Web of Science ®Google Scholar
• KING TS, ELIA M, HUNTER JO: Abnormal colonic fermentation in irritable bowel syndrome. Lancet (1998) 352:1187–1189.
   PubMed Web of Science ®Google Scholar
• CAMILLERI M: Management of the irritable bowel syndrome. Gastroenterology (2001) 120:652–668.
   PubMed Web of Science ®Google Scholar
• ••Great review of management of IBS.
   Google Scholar
• O'SULLIVAN MA, MAHMUD N, KELLEHER DP et al: Patient knowledge and educational needs in irritable bowel syndrome. Eur. I Gastroenterol Hepatol. (2000) 12:3–4.
   PubMedGoogle Scholar
• OWENS DM, NELSON DK, TALLEY NJ: The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann. Intern. Med. (1995) 122:107–112.
   PubMed Web of Science ®Google Scholar
• JONES VA, MCLAUGHLAN P, SHORTHOUSE M, WORKMAN E, HUNTER JO: Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. Lancet (1982) 2:1115–1117.
   PubMed Web of Science ®Google Scholar
• MUELLER-LISSNER SA: Effect of wheat bran on weight of stool and gastrointestinal transit time: a meta-analysis. BE Med. (1988) 296:615–617.
   PubMedGoogle Scholar
• JAILWALA J, IMPERIALE TF, KROENKE K: Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann. Intern. Med. (2000) 133:136–147.
   PubMed Web of Science ®Google Scholar
• HILLMAN LC, STACE NH, POMARE EW: Irritable bowel patients and their long-term response to a high fiber diet. Am. J. Gastroenterol (1984) 79:1–7.
   PubMedGoogle Scholar
• WHORWELL PJ, PRIOR A, FARAGHER EB: Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet (1984) 2:1232–1234.
   PubMed Web of Science ®Google Scholar
• WHORWELL PJ, PRIOR A, COLGAN SM: Hypnotherapy in severe irritable bowel syndrome: further experience. Gut (1987) 28:423–425.
   PubMed Web of Science ®Google Scholar
• HARVEY RE HINTON RA, GUNARY RM, BARRY RE: Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome. Lancet (1989) 1:424–425.
   PubMedGoogle Scholar
• PRIOR A, COLGAN SM, WHORWELL PJ: Changes in rectal sensitivity after hypnotherapy in patients with irritable bowel syndrome. Gut (1990) 31:896–898.
   PubMed Web of Science ®Google Scholar
• HOUGHTON LA, HEYMAN DJ, WHORWELL PJ: Symptomatology, quality of life and economic features of irritable bowel syndrome-the effect of hypnotherapy. Aliment. Pharm. Ther (1996) 10:91–95.
   PubMed Web of Science ®Google Scholar
• VIDAKOVIC-VUKIC M: Hypnotherapy in the treatment of irritable bowel syndrome: methods and results in Amsterdam. Scand. Gastroenterol (1999) 230(Suppl.):49–51.
   Google Scholar
• FORBES A, MACAULEY S, CHIOTAKAKOU-FALIAKOU E: Hypnotherapy and therapeutic audiotape: effective in previously unsuccessfully treated irritable bowel syndrome ?Int. J. Colorer] Dis. (2000) 15:328–334.
   PubMed Web of Science ®Google Scholar
• GONSALKORALE WM, HOUGHTON LA, WHORWELL PJ: Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. Am. J. Gastroenterol (2002) 97:954–961.
   PubMed Web of Science ®Google Scholar
• GREENE B, BLANCHARD EB: Cognitive therapy for irritable bowel syndrome. 'Consul Clin. Psycho] (1994) 62:576–582.
   PubMed Web of Science ®Google Scholar
• PAYNE A, BLANCHARD EB: A controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome. J. Consul. Clin. Psycho] (1995) 63:779–786.
   PubMed Web of Science ®Google Scholar
• DARNLEY SE, KENNEDY T, JONES R, CHALDER T, WESSLEY S: A randomised controlled trial of the addition of cognitive behavioural therapy (CBT) to antispasmodic therapy for irritable bowel syndrome (IBS) in primary care (Abstr). Gastroenterology (2002) 122:A–69.
   Google Scholar
• CANN PA, READ NW, HOLDSWORTH CD, BARENDS D: Role of loperamide and placebo in management of irritable bowel syndrome. DV. Dis. Sci. (1984) 29:239–247.
   PubMed Web of Science ®Google Scholar
• EFSKIND PS, BERNKLEV T, VATN MH: A double-blind, placebo-controlled trial with loperamide in irritable bowel syndrome. Scand. Gastroenterol (1996) 31:463–468.
   PubMed Web of Science ®Google Scholar
• MALCOLM A, CAMILLERI M, KOST L, BURTON DD, FETT SL, ZINSMEISTER AR: Towards identifying optimal doses for a2 adrenergic modulation of colonic and rectal motor and sensory function. AIM]. Pharm. Ther. (2000) 14:783–793.
   PubMed Web of Science ®Google Scholar
• VIRAMONTES BE, MALCOLM A, CAMILLERI M et al: Effects of an oc2-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am. J. Physiol (2001) 28:G1468–G1476.
   Google Scholar
• CAMILLERI M, KIM D-Y, MCKINZIE S et al.: Clonidine in diarrhea-predominant irritable bowel syndrome (D-IBS): a randomized, placebo-controlled, dose response study (Abstr). Gastroenterology (2002) 122:A–59.
   Google Scholar
• CAMILLERI M: Management of the irritable bowel syndrome. Gastroenterology (2001) 120:652–668.
   PubMed Web of Science ®Google Scholar
• THAYSEN EH, PEDERSEN L: Idiopathic bile salt catharsis. Gut (1976) 17:965–970.
   PubMed Web of Science ®Google Scholar
• LUMAN W, WILLIAMS AJ, MERRICK MV, EASTWOOD MA: Idiopathic bile acid malabsorption: long-term outcome. Eur. Gastroenterol Hepatol (1995) 7:641–645.
   PubMed Web of Science ®Google Scholar
• PASHANKAR DS, LOENING-BAUCKE V, BISHOP WP: Long-term efficacy and safety of polyethylene glycol 3350 (PEG) for the treatment of chronic constipation and encopresis in children (Abstr). Gastroenterology (2002) 122:AA–318.
   Google Scholar
• CUPPOLETTI J, MALINOWSKA DH, TEWARI KP, SHERRY AM, PATCHEN ML, UENO R: Recombinant and native intestinal cell CIC-2 CL-channels are activated by RU-0211 (Abstr). Gastroenterology (2002) 122:A–538.
   Google Scholar
• JOHANSON JF, GARGANO MA, PATCHEN ML, UENO R: Efficacy and safety of a novel compound, RU-0211, for the treatment of constipation (Abstr). Gastroenterology (2002) 122:A–315.
   Google Scholar
• BONNAFOUS C, BUENO L, GRIFFIN PH, SCHNEIER H, ROVATI LC, D'AMATO M: Influence of dexloxiglumide on visceromotor and pain response induced by rectal distension in rats. Gastroenterology (2002) 122:A–527.
   Google Scholar
• HAWKES ND, RHODES J, EVANS B, HAWTHORNE B, THOMAS G: Naloxone treatment for irritable bowel syndrome - a pilot study. Gastroenterology (2002) 122:A–552.
   Google Scholar
• POYNARD T, REGIMBEAU C, BENHAMOU Y: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Alim. Pharm. Ther. (2001) 15:355–361.
   PubMed Web of Science ®Google Scholar
• PAGE JG, DIRNBERGER GM: Treatment of the irritable bowel syndrome with bentyl (dicyclomine hydrochloride). J. Gastroenterol (1981) 3:153–156.
   Google Scholar
• RITCHIE JA, TRUELOVE SC: Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. Br. Med. J. (1979) 1:376–378.
   PubMed Web of Science ®Google Scholar
• NIGAM P KAPOOR KK, RASTOG CK, KUMAR A, GUPTA AK: Different therapeutic regimens in irritable bowel syndrome. I Assa Phys. India (1984) 32(12):1041–1044.
   PubMedGoogle Scholar
• DAPOIGNY M, ABITBOL JL, FRAITAG B: Efficacy of peripheral K agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig. Dis. Sci. (1995) 40:2244–2249.
   PubMed Web of Science ®Google Scholar
• DELVAUX M, LOU VEL D, LAGIER E, SCHERRER B, ABITBOL JL FREXINOS J: The K agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology (1999) 116:38–45.
   PubMed Web of Science ®Google Scholar
• DELGADO-AROS S, CHIAL H, FERBER I et al.: The K-opioid agonist asimadoline decreases satiety and fasting colonic tone in humans (Abstr). Gastroenterology (2002) 122:A–59.
   Google Scholar
• GAULTIER E, EMONDS-ALT X, FIORAMONTI J, BUENO L: NK2 and NK 3 receptor antagonists, 5R48968 and SR142801, reduce colonic hypersensitivity induced by inflammation or stress in rats, but do not modify colonic transit time. Gastroenterology (2002) 122:A–526.
   Google Scholar
• MILLION M, MCROBERTS JA, MAYER E, GRIGORIADIS D, TACHE Y: A novel water soluble CRF1 antagonist prevents stress-induced visceral hyperalgesia and colonic motor response in rats. Gastroenterology (2002) 122:A–527.
   Google Scholar
• JACKSON JL, O'MALLEY PG, TOMKINS G, BALDEN E, SANTORO J, KROENKE K: Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am. Med. (2000) 108:65–72.
   PubMed Web of Science ®Google Scholar
• DROSSMAN DA: DDW 2003: Digestive Disease Week. Orlando, Florida, USA (18 May 2003) Abst.51737.
   Google Scholar
• GORARD DA, LIBBY GW, FARTHING MJ: Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig. Dis. Sci (1995) 40:86–95.
   PubMed Web of Science ®Google Scholar
• CREED F, FERNANDES L, GUTHRIE E et al.: North of England IBS Research Group. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology (2003) 124:303–317.
   Google Scholar
• KIRSCH MA, LOUIE AK: Paroxetine and irritable bowel syndrome. Am. Psych. (2000) 157:1523–1524.
   Google Scholar
• EMMANUEL NP, LYDIARD RB, CRAWFORD M: Treatment of irritable bowel syndrome with fluvoxamine (letter). Am. J. Psychiatry (1997) 154:711–712.
   PubMedGoogle Scholar
• CLOUSE RE, LUSTMAN PJ, GEISMAN RA, ALPERS DH: Antidepressant therapy in 138 patients with irritable bowel syndrome: a 5-year clinical experience. Aliment. Pharmacol Ther. (1994) 8:409–416.
   PubMed Web of Science ®Google Scholar
• BROEKAERT D, VOS R, GEVERS A-M et al.: A double-blind randomised placebo-controlled trial of citalopram, a selective serotonin reuptake inhibitor, in irritable bowel syndrome (Abstr). Gastroenterology (2001) 120:A–641.
   Google Scholar
• KUIKEN SD, BURGERS P, TYTGAT GNJ: Fluoxetine (Prozac) for the treatment of irritable bowel syndrome: a randomized, controlled clinical trial (Abstr). Gastroenterology (2002) 122:A–551.
   Google Scholar
• MIURA M, LAWSON DC, CLARY EM, MANGEL AW, PAPPAS TN: Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist. Dig. Dis. Sci. (1999) 44:20–24.
   PubMed Web of Science ®Google Scholar
• KOZLOWSKI: The 5-HT3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut (2000) 46:474–480.
   PubMed Web of Science ®Google Scholar
• CLAYTON NM, SARGENT R, BUTLER A et al.: The pharmacological properties of the novel selective 5-HT3receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat. Neurogastroenterol Mod" (1999) 11:207–217.
   Google Scholar
• BUSH TG, SPENCER NJ, WATTERS N, SANDERS KM, SMITH TK: Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro. Am. J. Physiol (2001) 281:G974–G983.
   Google Scholar
• AUDOLFSSON G, BAYGUINOV O, YAMAMOTO T et al.: Review article: effects of the 5-HT3receptor antagonist alosetron on neuromuscular transmission in canine and human intestinal muscle. Alim. Pharm. Ther. (1999) 13\(Supp1.2):39–47.
   Google Scholar
• HOUGHTON LA, FOSTER JIVI, WHORWELL PJ: Alosetron, a 5-HT3receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. AIM]. Pharm. The]: (2000) 14:775–782.
   Google Scholar
• THUMSHIRN M, COULIE B, CAMILLERI M, ZINSMEISTER AR, BURTON DD, VAN DYKE C: Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel. AIM]. Pharm. Ther (2000) 14:869–878.
   PubMedGoogle Scholar
• CAMILLERI M, MAYER EA, DROSSMAN DA et al.: Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Alim. Pharm. Ther. (1999) 13:1149–1159.
   PubMed Web of Science ®Google Scholar
• CAMILLERI M, NORTHCUTT AR, KONG S, DUKES GE, MCSORLEY D, MANGEL AW: Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet (2000) 355:1035–1040.
   PubMed Web of Science ®Google Scholar
• CAMILLERI M, CHEY WY, MAYER EA et al.: A randomized controlled clinical trial of the serotonin Type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch. Intern. Med. (2001) 161:1733–1740.
   PubMed Web of Science ®Google Scholar
• BARDHAN KD, BODEMAR G, GELDOF H et al: A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Alim. Pharm. Ther. (2000) 14:23–34.
   PubMed Web of Science ®Google Scholar
• WATSON ME, LACEY L, KONG S et al: Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol (2001) 96:455–459.
   PubMed Web of Science ®Google Scholar
• WOLFE SG, CHEY WY, WASHINGTON MK et al.: Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am..! Gastroenterol (2001) 96:803–811.
   PubMed Web of Science ®Google Scholar
• OLDEN K, DEGARMO RG, JHINGRAN P et al.: Lotronex Investigator Team. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol (2002) 97:3139–3146.
   Google Scholar
• FRIEDEL D, THOMAS R, FISHER RS: Ischemic colitis during treatment with alosetron. Gastroenterology (2001) 120:557–560.
   PubMed Web of Science ®Google Scholar
• STACHER G, WEBER U, STACHER-JANOTTA G et al: Effects of the 5-HT3 antagonist cilansetron versus placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial. BE J. Pharm. (2000) 49:429–436.
   Google Scholar
• CARAS S, KRAUSE G, BIESHEUVEL E, STENBORN C: Cilansetron shows efficacy in non-constipated irritable bowel patients independent of the definition by Rome I or Rome II. Gastroenterology (2001) 120:A217.
   Web of Science ®Google Scholar
• PFANNKUCHE HJ, BUHL T, GAMSE R, HOYER D, MATTES H, BUCHHEIT KH: The properties of a new prokinetically-active drug, SDZ HTF 919. Neurogastroenterol Motility (1995) 7: 280.
   Google Scholar
• GRIDER JR, FOXX-ORENSTEIN E, JIN JG: 5-Hydroxytryptamine 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology (1998) 115:370–380.
   PubMed Web of Science ®Google Scholar
• JIN JG, FOXX-ORENSTEIN AE, GRIDER JR: Stimulation of colonic propulsion by 5-HT4 receptor agonist synergism by 8-opioid receptor antagonists. Gastroenterology (1997) 112:A754.
   Google Scholar
• SCHIKOWSKI A, THEWISSEN M, MATHIS C, ROSS HG, ENCK P: Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterology & Mon] (2002) 14:221–227.
   PubMed Web of Science ®Google Scholar
• SCHIKOWSKI A, MATHIS C, THEWISSEN M et al: Dose-dependent modulation of rectal afferent sensivity by a 5-HT receptor agonist. Gastroenterology (1999) 116:A643.
   PubMedGoogle Scholar
• COELHO AM, ROVINA P, FIORAMONTI J, BUENO L: Antinociceptive properties of HTF 919 (tegaserod), a 5-HT4 receptor partial agonist, on colorectal distension in rats. Gastroenterology (2000) 118:A835.
   PubMedGoogle Scholar
• DEGEN L, MATZINGER D, MERZ M eta].: Tegaserod, a 5-HT4receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment. Phannacol Ther (2001) 15:1745–1751.
   Google Scholar
• PRATHER CM, CAMILLERI M, ZINSMEISTER AR, MCKINZIE S, THOMFORDE G: Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology (2000) 118:463–468.
   PubMed Web of Science ®Google Scholar
• MULLER-LISSNER SA, FUMAGALLI I, BARDHAN KD et al: Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Ailment. Pharmacol Ther. (2001) 15:1655–1666.
   PubMed Web of Science ®Google Scholar
• NOVICK J, MINER P, KRAUSE R et al A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Ailment. Pharmacol Ther. (2002) 16:1877–1888.
   PubMed Web of Science ®Google Scholar
• FIDELHOLTZ J, SMITH W, RAWLS J et al: Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. Am. I Gastroenterol (2002) 97:1176–1181.
   PubMedGoogle Scholar
• TOUGAS G, SNAPE WJ Jr, OTTEN MH et al.: Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment. Pharmacol Ther. (2002) 16:1701–1708.
   PubMed Web of Science ®Google Scholar
• DRICI MD, EBERT SN, WANG WX et al.: Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. J. Cardio. Pharm. (1999) 34:82–88.
   PubMedGoogle Scholar
• MORGANROTH J, RUEGG PC, DUNGER-BALDAUF C, APPEL-DINGEMANSE S, BLIESATH H, LEFKOWITZ M: Tegaserod, a 5-hydroxytryptamine Type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am. J. Gastroenterol (2002) 97:2321–2327.
   PubMed Web of Science ®Google Scholar
• POEN AC, FELT-BERSMA RJ, VAN DONGEN PA, MEUWISSEN SG: Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Ailment. Pharmacol Ther. (1999) 13:1493–1497.
   PubMed Web of Science ®Google Scholar
• BOURAS EP, CAMILLERI M, BURTON DD, MCKINZIE S: Selective stimulation of colonic transit by the benzofuran 5 agonist, prucalopride, in healthy humans. Gut (1999) 44:682–686.
   PubMed Web of Science ®Google Scholar
• DE SCHRYVER AM, ANDRIESSE GI, SAMSOM M, SMOUT AJ, GOOSZEN HG, AKKERMANS LM: The effects of the specific 5HT4 receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment. Pharmacol Ther. (2003) 16:603–612.
   Google Scholar
• BOURAS EP, CAMILLERI M, BURTON DD, THOMFORDE G, MCKINZIE S, ZINSMEISTER AR: Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology (2001) 120:354–360.
   PubMed Web of Science ®Google Scholar
• SLOOTS CE, POEN AC, KERSTENS R et al.: Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Ailment. Pharmacol Ther. (2002) 16:759–767.
   PubMed Web of Science ®Google Scholar
• NIEDZIELIN K, KORDECKI H, BIRKENFELD B: A controlled, double-blind, randomized study on the efficacy of Lactobacillusp/antarum 299V in patients with irritable bowel syndrome. Eur. Castro. Hepatol. (2001) 13:1143–1147.
   PubMed Web of Science ®Google Scholar
• HALPERN GM, PRINDIVILLE T, BLANKENBURG M, HSIA T, GERSHWIN ME: Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am. J. Castro. (1996) 91:1579–1585.
   PubMed Web of Science ®Google Scholar
• GADE J, THORN P: Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. Scand. J. Prim. Health Care (1989) 7:23–26.
   PubMedGoogle Scholar
• PRIMENTEL M, CHOW EJ, LIN HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am. Castro. (2000) 95:3503–3506.
   PubMedGoogle Scholar
• COULIE B, SZARKA LA, CAMILLERI M: Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology (2000) 119:41–50.
   PubMed Web of Science ®Google Scholar